Feb 27, 2011 - 4:55 am
Japan says yes.
According to a citation from a detailed Japanese study published in ASCO’s Journal of Clinical Oncology, patients in Japan are more often treated with hormonal therapy than in the USA, and the reasons behind are due to doctor’s “choice” rather than in view of the characteristics of the patient’s disease. The study indicates high rates of Progression-free survival in clinical stage II, III and IV patients treated with HT. This is an interesting finding for those diagnosed with Localized PCa, who may include HT as their prime treatment, instead of a radical approach.
Here is part of the document citations. For the full text and study visit this site;
“…The role played by endocrine therapy for localized prostate cancer in Japan differs markedly from that in Europe and the United States. According to the prostate registry operated by JUA (11), which included 4529 registered patients who were diagnosed with prostate cancer in 2000, ADT was selected as an initial treatment for 45.9% of the 2671 patients with stage T1c-T3N0M0 prostate cancer. In the United States, the number of cases with localized prostate cancer treated with ADT has also been increasing, according to the CaPSURE report and the SEER data, but the number in the United States is less than half of that in Japan.
In Europe and the United States, few high-quality clinical studies have been carried out on ADT used for the treatment of localized prostate cancer, and clinical evidence is absent. Then, why has the use of ADT for the treatment of localized prostate cancer been increasing in the United States in recent years? Shahinian et al. viewed selection of ADT as a Wennberg’s practice style hypothesis and explained that it is primarily dependent on the view of individual urologists.
The best to my comrades and newbies.